PL409825A1 - Preparat do mobilizacji małych komórek pluripotentnych (VSEL) oraz komórek macierzystych progenitorowych (HSPC) CD 34+ ze szpiku kostnego do krwi obwodowej i zastosowanie metforminy (N, N-dimetylobiguanidu) - Google Patents

Preparat do mobilizacji małych komórek pluripotentnych (VSEL) oraz komórek macierzystych progenitorowych (HSPC) CD 34+ ze szpiku kostnego do krwi obwodowej i zastosowanie metforminy (N, N-dimetylobiguanidu)

Info

Publication number
PL409825A1
PL409825A1 PL409825A PL40982514A PL409825A1 PL 409825 A1 PL409825 A1 PL 409825A1 PL 409825 A PL409825 A PL 409825A PL 40982514 A PL40982514 A PL 40982514A PL 409825 A1 PL409825 A1 PL 409825A1
Authority
PL
Poland
Prior art keywords
cells
hspc
vsel
metformin
bone marrow
Prior art date
Application number
PL409825A
Other languages
English (en)
Inventor
Krzysztof Marycz
Agnieszka Śmieszek
Original Assignee
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością filed Critical Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL409825A priority Critical patent/PL409825A1/pl
Priority to EP15798556.5A priority patent/EP3207125A1/en
Priority to PCT/IB2015/057834 priority patent/WO2016059554A1/en
Publication of PL409825A1 publication Critical patent/PL409825A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Przedmiotem wynalazku jest preparat do mobilizacji małych komórek pluripotentnych (VSEL) oraz komórek macierzystych progenitorowych (HSPC) CD34+ ze szpiku kostnego do krwi obwodowej, charakteryzujący się tym, że zawiera metforminę, a także zastosowanie metforminy do mobilizacji małych komórek pluripotentnych VSEL oraz komórek macierzystych progenitorowych (HSPC) CD34+ ze szpiku kostnego do krwi obwodowej i do stosowania w leczeniu lub zapobieganiu stanów związanych z obniżonym potencjałem regeneracyjnym lub przyspieszonym starzeniem się komórek.
PL409825A 2014-10-17 2014-10-17 Preparat do mobilizacji małych komórek pluripotentnych (VSEL) oraz komórek macierzystych progenitorowych (HSPC) CD 34+ ze szpiku kostnego do krwi obwodowej i zastosowanie metforminy (N, N-dimetylobiguanidu) PL409825A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL409825A PL409825A1 (pl) 2014-10-17 2014-10-17 Preparat do mobilizacji małych komórek pluripotentnych (VSEL) oraz komórek macierzystych progenitorowych (HSPC) CD 34+ ze szpiku kostnego do krwi obwodowej i zastosowanie metforminy (N, N-dimetylobiguanidu)
EP15798556.5A EP3207125A1 (en) 2014-10-17 2015-10-13 Preparation for pluripotent very small embryonic/epiblast-like stem cells (vsels) and hematopoietic stem/progenitor cells (hspc) cd34+ mobilisation from bone marrow to peripheral blood and the use of metformin (n,n-dimethylbiguanide)
PCT/IB2015/057834 WO2016059554A1 (en) 2014-10-17 2015-10-13 Preparation for pluripotent very small embryonic/epiblast-like stem cells (vsels) and hematopoietic stem/progenitor cells (hspc) cd34+ mobilisation from bone marrow to peripheral blood and the use of metformin (n,n-dimethylbiguanide)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL409825A PL409825A1 (pl) 2014-10-17 2014-10-17 Preparat do mobilizacji małych komórek pluripotentnych (VSEL) oraz komórek macierzystych progenitorowych (HSPC) CD 34+ ze szpiku kostnego do krwi obwodowej i zastosowanie metforminy (N, N-dimetylobiguanidu)

Publications (1)

Publication Number Publication Date
PL409825A1 true PL409825A1 (pl) 2016-04-25

Family

ID=54697615

Family Applications (1)

Application Number Title Priority Date Filing Date
PL409825A PL409825A1 (pl) 2014-10-17 2014-10-17 Preparat do mobilizacji małych komórek pluripotentnych (VSEL) oraz komórek macierzystych progenitorowych (HSPC) CD 34+ ze szpiku kostnego do krwi obwodowej i zastosowanie metforminy (N, N-dimetylobiguanidu)

Country Status (3)

Country Link
EP (1) EP3207125A1 (pl)
PL (1) PL409825A1 (pl)
WO (1) WO2016059554A1 (pl)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130323197A1 (en) 2010-10-07 2013-12-05 University Of Louisville Research Foundation, Inc. Ifg-1 dependent modulation of vsels

Also Published As

Publication number Publication date
EP3207125A1 (en) 2017-08-23
WO2016059554A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL274154A (en) Compositions and methods for diluting CD117 plus cells
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
MY184859A (en) Oral care compositions
MX389228B (es) Composiciones para tratar el cabello.
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2019007187A (es) Composiciones para el cuidado bucal.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
PT3297641T (pt) Métodos de armazenamento de sangue total e respetivas composições
MX390493B (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EP4650000A3 (en) High concentration formulation
ES2948810T8 (en) Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX2020012893A (es) Formulaciones de proteinas.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2019005821A (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas.
PH12017501692A1 (en) Solid forms of menaquinols
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential